Aerovate Therapeutics, Inc.
AVTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $112 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $56 |
| Gross Profit | $0 | $0 | $0 | $56 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $22,010 | $22,547 | $0 | $1,531 |
| G&A Expenses | $5,391 | $5,231 | $3,387 | $4,872 |
| SG&A Expenses | $5,391 | $5,231 | $3,387 | $4,872 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27,401 | $27,778 | $3,387 | $6,403 |
| Operating Income | -$27,401 | -$27,778 | -$3,387 | -$6,403 |
| % Margin | – | – | – | -5,717% |
| Other Income/Exp. Net | $2,226 | -$4,356 | $869 | $1,028 |
| Pre-Tax Income | -$25,175 | -$32,134 | -$2,518 | -$5,375 |
| Tax Expense | $0 | $0 | $0 | $55 |
| Net Income | -$25,175 | -$32,134 | -$2,518 | -$5,430 |
| % Margin | – | – | – | -4,848.2% |
| EPS | -482.25 | -863.46 | -0.09 | -0.19 |
| % Growth | 44.1% | -959,300% | 52.6% | – |
| EPS Diluted | -482.25 | -863.46 | -0.09 | -0.19 |
| Weighted Avg Shares Out | 39,584 | 28,431 | 28,985 | 28,611 |
| Weighted Avg Shares Out Dil | 39,584 | 28,431 | 28,985 | 28,612 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,254 | $1,828 | $871 | $1,028 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $8 |
| EBITDA | -$25,175 | -$27,778 | -$3,387 | -$6,395 |
| % Margin | – | – | – | -5,709.8% |